What therapeutic approach is often used for patients with chronic Hepatitis C and moderate disease?

For patients with chronic Hepatitis C and moderate disease, the use of interferon plus ribavirin is a well-established therapeutic approach. This combination therapy aims to reduce the viral load of the hepatitis C virus (HCV) and promote viral eradication, enhancing the chances of achieving a sustained virological response (SVR).

Interferon, an antiviral agent with immunomodulatory effects, works by enhancing the immune system's ability to fight off the virus. Ribavirin, on the other hand, acts by interfering with viral replication. Together, these agents have been shown to improve treatment outcomes for patients with moderate liver disease due to Hepatitis C.

While other treatment options exist, such as direct-acting antivirals (DAAs), the combination of interferon and ribavirin remains a significant historical reference in the context of Hepatitis C treatment, particularly before the widespread adoption of DAAs which have largely replaced older therapies in most cases due to their superior efficacy and safety profiles.

Antiviral monotherapy is generally less effective, as it may not adequately target the virus or bolster the immune response alone. Immunosuppressants and corticosteroids are not appropriate treatment options for Hepatitis C as they may exacerbate the infection and impair the